skip to main content
- Two-Stage Phase II Oncology Clinical Trials Designs - Fei Ye and Yu Shyr
- Characteristics of 3+3 designs in phase I clinical trials - T Koyama
- Weighted Flexible Compound Covariate Method - Y Shyr and development team
- Power and Sample Size Estimation Software - Dupont and Plummer
- Mass Spectrometry Binning Software PSB - H Li,S Chen,D Hong, M Li, and Y Shyr
- Mass Spectrometry Binning Software GAB - H Li, S Chen,D Hong, M Li, and Y Shyr
- Mass Spectrometry Preprocessing Software waveSpec 0.9 - S Chen,D Hong, and Y Shyr
- Script of CSDA for Mass Spectrometry Preprocessing - S Chen
- Biostat Toolbox Excel Add-in - W Gray
- Risk Score Patient Survival - Mike Guo and Yu Shyr
- RNASeq Sample Size Estimation - Shilin Zhao, Chung-I Li and Yu Shyr
- RNASeq Sample Size Estimation By GLM - Chung-I Li and Yu Shyr
- Phase I two-stage mTPI design - Sheau-Chiann Chen and Yu Shyr
- Nascent RNA Sequencing Analysis - Jing Wang and Qi Liu
- Optimal Selection of Adaptive Designs in Phase I Oncology Clinical Trials - Sheau-Chiann Chen and Yu Shyr
